← Back to headlines
Mpm Bioventures Divests $617,000 Stake in Entrada Therapeutics
The venture capital firm reduced its holdings in the biotechnology company through recent market transactions, reflecting standard portfolio rebalancing activities.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
